RFRafaela de Souza Ferreira

Rafaela de Souza Ferreira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Rafaela de Souza Ferreira has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HEMATOPOIETIC CELL TRANSPLANTATION FOR JUVENILE MYELOMONOCYTIC LEUKEMIA AND OTHER MYELOPROLIFERATIVE NEOPLASMS

    by Neysimelia Costa Villela, Anita Frisanco Oliveira, Rafaela de Souza Ferreira, Gustavo Zamperlini, Andréia Cristina Fortes Bassani, Mariana Bohns Michalowski, Maria Lúcia de Martino Lee

    Juvenile myelomonocytic leukemia (JMML) is a rare and distinctive hematologic neoplasm affecting infants and younger children. Hyperactivation of the RAS signaling pathway is a central initiating event in JMML, which also delineates its various genetic and clinical subtypes. While a small percentage of children may achieve spontaneous clinical remission, allogeneic hematopoietic cell transplantation (HCT) remains the only possible cure for most JMML patients. In this article, we reviewed the indications of HCT in JMML. Other myeloproliferative diseases, such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis, are extremely rare in pediatrics and are briefly discussed.

  • Open Access

    Long-term follow-up after pediatric hematopoietic stem cell transplantation

    by Polliany Roberta Dorini Pelegrina, Roseane Vasconcelos Gouveia, Antonio Vaz de Macedo, Ana Karine Vieira, Gabriela Gaspar Filgueiras Landi, Julia Lopes, Osvaldo Alves de Menezes Neto, Rafaela de Souza Ferreira, Adriana Aparecida Siviero Miachon, Rita de Cássia Barbosa da Silva Tavares, et al.

    This article, part of the Pediatric Group consensus of the Brazilian Society of Bone Marrow Transplantation, addresses lifelong follow-up in pediatric hematopoietic stem cell transplant survivors. With the growing number of long-term survivors, specialized monitoring is essential, especially for high-risk groups such as infants, recipients of total body irradiation, and those with inherited bone marrow failure syndromes. The consensus outlines surveillance strategies for detecting and managing late complications, including chronic graft-versus-host disease and secondary effects. Multidisciplinary recommendations aim to optimize early intervention and quality of life, establishing a standardized follow-up framework for pediatric transplant care in Brazil.


  • Open Access

    Chronic graft-versus-host-disease

    by Adriana Mello Rodrigues, Rita de Cassia Barbosa da Silva Tavares, Antonio Vaz de Macedo, Carla Nolasco Monteiro Breviglieri, Marcia de Matos Silva, Mônica Alves, Rafaela de Souza Ferreira, Roseane Vasconcelos Gouveia, Luis Fernando Bouzas

    Chronic GvHD is a major cause of non-relapse morbidity and mortality after hematopoietic cell transplantation. Its incidence has increased due to more frequent use of unrelated and/or mismatched donors, reduced intensity conditioning regimens or intensified regimens and PBSC grafts. The first-line therapy for chronic GvHD is systemic corticosteroids associated with either CNI or sirolimus, as a steroid sparing agent. Since children are more susceptible to the long-term steroid side effects, development of steroid-free strategies for front-line therapy is crucial. Sirolimus seems to be an interesting choice due to its capacity of inhibiting T-cells preserving the Tregs cells and antifibrotic, antineoplastic and antiviral activities. FAM regimen (Fluticasone, Azitromycin and Montelucaste) is recommended in combination with systemic steroids for initial treatment of bronchiolitis obliterans. For steroid-refractory chronic GvHD, ruxolitinib is the standard of care, while extracorporeal photopheresis can be combined for better results, however treatment costs are limitations. Extracorporeal photopheresis, treatment that preserves graft-versus-leukemia effect due to its steroid sparing and immunomodulatory actions, and mesenchymal stem cells, another non-pharmacological strategy that can be combined with the options mentioned above in severe chronic GvHD. Since access to novel drugs and extracorporeal photopheresis or mesenchymal stem cells is tough, other options approved for the third line and beyond are ibrutinib, belumosudil and axatilimab. Conventional agents could be used such as imatinib, low dose-MTX, rituximab, however the expected response rates are lower. We reviewed clinical studies and published recommendations on pediatric chronic GVHD that were presented in debate rounds with GvHD experts of the Pediatric group of the Sociedade Brasileira de Terapia Celular e Transplante de Medula Óssea (SBTMO). The goal of this consensus is to standardize the prophylaxis, diagnosis, grading and treatment of chronic GvHD among Brazilian pediatric HCT centers, to improve post-transplant outcomes.